Key result
Sugammadex versus usual care had an estimated relative risk of bleeding events of 0.70 (95% CI 0.38-1.29), though definitive conclusions regarding patients on concomitant antiplatelets are not yet possible.
Why the study?
Does sugammadex increase the risk of postoperative bleeding in surgical patients receiving concomitant antiplatelet-anticoagulant therapy?
Population
Surgical patients receiving thromboprophylaxis after major hip or knee surgery
Comparison
Sugammadex vs Usual care
Design
Editorial
Authors
Loading...
This editorial highlights the need for further data to definitively rule out an increased risk of postoperative bleeding with sugammadex in surgical patients on combined antiplatelet and anticoagulant therapy.
Does sugammadex increase the risk of postoperative bleeding in surgical patients receiving concomitant antiplatelet-anticoagulant therapy?
Relative Risk: 0.7 (95% CI 0.38–1.29)
This editorial highlights the need for further data to definitively rule out an increased risk of postoperative bleeding with sugammadex in surgical patients on combined antiplatelet and anticoagulant therapy.
Michele Carron (2015) conducted a letter in Surgical patients receiving thromboprophylaxis after major hip or knee surgery. Sugammadex vs. Usual care was evaluated on Bleeding events (RR 0.70, 95% CI 0.38 to 1.29). Sugammadex versus usual care had an estimated relative risk of bleeding events of 0.70 (95% CI 0.38-1.29), though definitive conclusions regarding patients on concomitant antiplatelets are not yet possible.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: